KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Current Leases: 2019-2024

Historic Current Leases for Esperion Therapeutics (ESPR) over the last 6 years, with Dec 2024 value amounting to $2.7 million.

  • Esperion Therapeutics' Current Leases fell 13.02% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 13.02%. This contributed to the annual value of $2.7 million for FY2024, which is 76.50% up from last year.
  • As of FY2024, Esperion Therapeutics' Current Leases stood at $2.7 million, which was up 76.50% from $1.6 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Current Leases registered a high of $2.7 million during FY2024, and its lowest value of $384,000 during FY2022.
  • Moreover, its 3-year median value for Current Leases was $1.6 million (2023), whereas its average is $1.6 million.
  • Per our database at Business Quant, Esperion Therapeutics' Current Leases surged by 469.82% in 2020 and then tumbled by 72.41% in 2022.
  • Over the past 5 years, Esperion Therapeutics' Current Leases (Yearly) stood at $2.6 million in 2020, then plummeted by 46.19% to $1.4 million in 2021, then slumped by 72.41% to $384,000 in 2022, then skyrocketed by 304.43% to $1.6 million in 2023, then surged by 76.50% to $2.7 million in 2024.